EPCORE NHL-1
EPCORE NHL-1 was the pivotal single-arm study behind epcoritamab's approval; about half of complete responders are still in remission at three years.
ORR 63.1%, CR 38.9%; median DOR 15.5 months; 3-year follow-up: 53% of complete responders in ongoing remission, many with undetectable ctDNA. CRS 49.7% (grade 3: 2.5%).
Setting
R/R LBCL after ≥2 lines (single-arm expansion): epcoritamab monotherapy
Phase
Phase 2
Sponsor
Genmab / AbbVie
Registry
Headline result
ORR 63%, CR 39%.
Reported
2022
Enrolled
157
In plain words
What these results mean for people, not percentages
Objective response rateprimaryresponse endpoint
- 63.1 out of 100 people had their tumour shrink with Epcoritamab.
Complete response rateresponse endpoint
- 38.9 out of 100 people had their tumour shrink with Epcoritamab.
Be careful
- There was no comparison group, so this number cannot tell you how much of the effect is due to the treatment.
- A response rate counts how many people had their tumours shrink by a set amount; shrinking is encouraging but does not by itself show that people live longer or feel better.
- These results apply to the people the trial enrolled: R/R LBCL after ≥2 lines (single-arm expansion): epcoritamab monotherapy. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.